Search research articles
Contact Us
Filters
Showing results (91-100 of 116) with videos related to
Page
of 12
Sort By:
Cancer
|
February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
Do-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 21, 2021
Impact of COVID-19 on healthcare organisation and cancer outcomes
Aurelie Bardet, Alderic M Fraslin, Jamila Marghadi, et al.
International Journal of Cancer
|
April 23, 2014
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
Julien Hadoux, Judith Favier, Jean-Yves Scoazec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2024
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O<sup>6</sup>-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)
Thomas Walter, Thierry Lecomte, Julien Hadoux, et al.
Thyroid : Official Journal of the American Thyroid Association
|
August 19, 2025
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i>-Mutant Medullary Thyroid Cancer
Rossella Elisei, Lori J Wirth, Jaume Capdevila, et al.
Endocrine-Related Cancer
|
August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study
Julien Hadoux, Thomas Walter, Christina Kanaan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 6, 2025
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks
Sarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, et al.
Lancet (London, England)
|
February 25, 2024
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
Eric Baudin, Bernard Goichot, Alfredo Berruti, et al.
Trials
|
July 11, 2023
Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
Dana Hartl, Yann Godbert, Xavier Carrat, et al.
Trials
|
April 29, 2023
ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
Dana Hartl, Yann Godbert, Xavier Carrat, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 116) with videos related to
Sort By:
Page
of 12
Cancer
|
February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
Do-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 21, 2021
Impact of COVID-19 on healthcare organisation and cancer outcomes
Aurelie Bardet, Alderic M Fraslin, Jamila Marghadi, et al.
International Journal of Cancer
|
April 23, 2014
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
Julien Hadoux, Judith Favier, Jean-Yves Scoazec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2024
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O<sup>6</sup>-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)
Thomas Walter, Thierry Lecomte, Julien Hadoux, et al.
Thyroid : Official Journal of the American Thyroid Association
|
August 19, 2025
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i>-Mutant Medullary Thyroid Cancer
Rossella Elisei, Lori J Wirth, Jaume Capdevila, et al.
Endocrine-Related Cancer
|
August 3, 2022
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study
Julien Hadoux, Thomas Walter, Christina Kanaan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 6, 2025
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks
Sarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, et al.
Lancet (London, England)
|
February 25, 2024
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
Eric Baudin, Bernard Goichot, Alfredo Berruti, et al.
Trials
|
July 11, 2023
Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
Dana Hartl, Yann Godbert, Xavier Carrat, et al.
Trials
|
April 29, 2023
ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
Dana Hartl, Yann Godbert, Xavier Carrat, et al.
Page
of 12